Biotech Values

[jq1234]

Maybe business decision coincides with regulatory decision in this case. IF FDA had strongly suggested they'd like to have HIV co-infection in initial NDA at EOP2, most companies would follow. Many companies I know paid prices for following their own business decisions while disregarding regulatory guidance/decision.